Health Care & Life Sciences » Pharmaceuticals | Hwail Pharmaceutical Co. Ltd.

Hwail Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
4,209
4,132
5,453
6,382
2,665
Depreciation, Depletion & Amortization
1,422
1,871
2,772
2,913
2,727
Other Funds
361
585
4,080
2,320
1,949
Funds from Operations
5,993
6,588
4,145
6,975
7,341
Changes in Working Capital
979
9,372
11,050
2,607
996
Net Operating Cash Flow
6,972
2,784
6,905
9,582
8,337
Capital Expenditures
9,185
1,537
1,566
413
514
Sale of Fixed Assets & Businesses
16
27
68
31
-
Purchase/Sale of Investments
1,972
993
4,664
6,879
1,166
Net Investing Cash Flow
10,958
192
3,465
7,699
524
Cash Dividends Paid - Total
1,313
1,352
1,352
2,028
2,028
Issuance/Reduction of Debt, Net
5,173
54
5,151
11,722
1,336
Net Financing Cash Flow
3,860
1,406
3,799
13,750
3,364
Net Change in Cash
208
3,994
398
3,640
5,189
Free Cash Flow
2,213
4,195
7,960
9,169
7,824
Other Sources
728
2,995
300
1,490
14
Exchange Rate Effect
82
4
38
110
308
Other Uses
545
300
-
288
143

About Hwail Pharmaceutical Co.

View Profile
Address
57 Jeyakgongdan 3-gil
Hwaseong GY 18622
Korea, Republic Of
Employees -
Website http://www.hwail.com
Updated 09/14/2018
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following businesses: Pharmaceutical Raw Material, Cephalosporin Antibiotic, Functional Health Food Ingredient. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.